<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411176</url>
  </required_header>
  <id_info>
    <org_study_id>NPO-11-02/C-02</org_study_id>
    <nct_id>NCT01411176</nct_id>
  </id_info>
  <brief_title>Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy</brief_title>
  <official_title>Phase III Placebo-controlled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (Randomized, Double-blind, Parallel-assignment, Placebo-controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with early gastric cancer, who require therapeutic upper gastrointestinal endoscopy,&#xD;
      such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), will&#xD;
      receive intragastric spraying of NPO-11 or placebo. The superiority of NPO-11 to placebo as&#xD;
      anti-peristaltic agent will be verified in a randomized, double-blind, parallel-assignment&#xD;
      design based on the proportion of patients with suppressed gastric peristalsis during the&#xD;
      procedures. The degree of gastric peristalsis is assessed by an independent committee.&#xD;
&#xD;
      The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions&#xD;
      (ADRs) observed between administration and seven days after administration in comparison with&#xD;
      the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients had no or mild peristalsis during the therapeutic procedures</measure>
    <time_frame>60 minutes</time_frame>
    <description>No or mild gastric peristalsis is defined as when patients have no or suppressed gastric peristalsis during the therapeutic procedure. The degree of gastric peristalsis in the time periods is assessed by an independent committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of peristalsis-suppressing effect</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty level of the therapeutic procedure</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-piece resection rate with tumor-free margin</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and adverse drug reactions</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml NPO-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 ml NPO-11(Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menthol</intervention_name>
    <description>20 mL NPO-11 in a prefilled plastic syringe</description>
    <arm_group_label>Menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is included same additives as active comparator.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        inpatients or outpatients of either sex who require therapeutic upper gastrointestinal&#xD;
        endoscopy (EMR or ESD) and meet the criteria (1)-(4) below will be enrolled in the study.&#xD;
        Patients have to provide written informed consent for voluntary participation in the study.&#xD;
        The criteria (2) and (3) will be confirmed by the endoscopic observation just before&#xD;
        starting the intended treatment.&#xD;
&#xD;
          1. Patients with an early gastric cancer located in the lower third of the stomach, who&#xD;
             require therapeutic upper gastrointestinal endoscopy (EMR or ESD) (except for those&#xD;
             with an intended treatment by using a scope of &lt;9 mm in diameter)&#xD;
&#xD;
          2. Differentiated -type intramucosal gastric cancer or the suspected lesion, â‰¤ 2 cm in&#xD;
             size, no ulcer finding&#xD;
&#xD;
          3. Patients with a single intended lesion for the treatment&#xD;
&#xD;
          4. Patients who are older than 20 years at the time of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria will be excluded from the study beforehand.&#xD;
        The criteria (3) to (5) will be confirmed by the endoscopic observation just before&#xD;
        starting the intended treatment.&#xD;
&#xD;
          1. Patients with a history of surgery to the upper gastrointestinal tract&#xD;
&#xD;
          2. Patients who require emergency endoscopy&#xD;
&#xD;
          3. Patients with severe gastric stenosis or deformation which makes observation of&#xD;
             gastric peristalsis difficult&#xD;
&#xD;
          4. Patients who require emergency endoscopic treatment except for the intended lesion&#xD;
&#xD;
          5. Patients with a lesion extended to the pyloric ring&#xD;
&#xD;
          6. Patients with an ongoing cancer treatment (chemotherapy or radiotherapy)&#xD;
&#xD;
          7. Patients with pacemaker&#xD;
&#xD;
          8. Patients with known bleeding tendency or Patients with difficulty of antithrombogenic&#xD;
             agents withdrawal&#xD;
&#xD;
          9. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil&#xD;
&#xD;
         10. Patients with contraindications to glucagon&#xD;
&#xD;
         11. Patients with contraindications to benzodiazepines, pethidine hydrochloride, and&#xD;
             epinephrine&#xD;
&#xD;
         12. Pregnant or lactating women, women of childbearing potential, or women who plan to&#xD;
             become pregnant during the study&#xD;
&#xD;
         13. Patients who have received other investigational drugs within four months before&#xD;
             consent or who are participating in other clinical studies&#xD;
&#xD;
         14. Patients otherwise ineligible for participation in the study in the investigator's&#xD;
             opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nihon Pharmaceutical Co., Ltd</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>upper gastrointestinal endoscopy</keyword>
  <keyword>suspected gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

